Nazila Habibizad files SEC Form 4 disclosures for Global Blood Therapeutics, Inc.. They have made 1 open-market trade across 1 company since 2022, most recently 2022-10-05.
CIK 0001913961
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
0 open-market purchases, against 1 sale. Too few scored purchases to measure a record yet.
| Ticker | Shares | Value |
|---|---|---|
| GBT | 39,498 | $2.7M |
Shares reported on the most recent Form 4, priced at the 2022-10-04 close.
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| GBT | SELL | 2022-08-18 | 2022-08-19 | $67.19 | $629K | +1.2% | +1.4% | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.